EX-FILING FEES 2 d559315dexfilingfees.htm EX-FILING FEES EX-FILING FEES

 

Exhibit 107

Calculation of Filing Fee Tables

424(b)(5)

(Form Type)

IDEAYA Biosciences, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

 

                 
     Security 
Type 
  Security Class Title   Fee
Calculation
or Carry
Forward
Rule
 

Amount

Registered

 

Proposed

Maximum

Offering

Price

Per Unit

 

Maximum

Aggregate

Offering

Price(1)

  Fee Rate  

Amount of

Registration

Fee(1)

 
Newly Registered Securities
                 

Fees to

Be Paid

  Equity   

Common Stock, 

$0.0001 par  value per share 

  Rule 457 (r)    6,117,022(2)    $23.50    $143,750,017    0.00014760    $21,217.50
                 

Fees to

Be Paid

  Equity    Pre-funded warrants to purchase common stock   Rule 457(r)    319,150    $23.50(3)    _____(3)    0.00014760    $—
                 

Fees

Previously

Paid

  N/A    N/A    N/A    N/A    N/A    N/A      N/A
 
Carry Forward Securities
                 

Carry Forward

Securities

  N/A    N/A    N/A    N/A      N/A       
           
    Total Offering Amounts      $143,750,017      $21,217.50(1)
           
    Total Fees Previously Paid         
           
    Total Fee Offsets          $—
           
    Net Fee Due                $21,217.50

 

(1)

In accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended (the “Securities Act”), the registrant initially deferred payment of all of the registration fees for the Registration Statement on Form S-3 (Registration No. 333-272936), filed on June 26, 2023.

(2)

Includes 797,872 shares of common stock that the underwriters have an option to purchase and 319,150 shares of common stock that are issuable upon the exercise of pre-funded warrants referenced below.

(3)

Represents the sum of the pre-funded warrants sales price of $23.4999 per pre-funded warrant and the exercise price of $0.0001 per share issuable pursuant to the pre-funded warrants. Pursuant to Securities and Exchange Commission staff interpretation, the entire fee is allocated to the common stock underlying the pre-funded warrants.